Immunological monitoring and clinical trials of biological response modifiers.
Baseler
M W
MW
Program Resources Inc./Dyncorp, National Cancer Institute, Frederick Cancer Research and Development Center, MD.
Kopp
W C
WC
Urba
W J
WJ
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007372:Interferons / Q000627:therapeutic use; D007378:Interleukins / Q000009:adverse effects / Q000627:therapeutic use; D015166:Monitoring, Immunologic; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use
D007155:Immunologic Factors; D007378:Interleukins; D014409:Tumor Necrosis Factor-alpha; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C035104:muramylNAc-Ala-isoGln-Lys-tripeptide; D007372:Interferons